|
Re: FDA finds Avastin doesn't extend lives in BC patients... ?
Flip side, when company does go after a "targeted" drug, i.e. t-dm1 for Her2+ mbc treatment, FDA insists that "all" prior approved bc therapies, targeted or not, are included in the study. Is this a situation of having your cake and eating it too?
|